ArticlePrenatal diagnosis2026
Impact of Prenatal Cell-Free DNA Screening on Sex Chromosome Aneuploidy Diagnoses in Infants and Children.
Article in Prenatal diagnosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePrenatal cell-free DNA (cfDNA) screening increasingly includes sex chromosome aneuploidy (SCA) screening, despite variation in test accuracy and expressivity. This study evaluated changes in pediatric SCA diagnostic rates before and after the introduction of cfDNA screening.
methodA controlled interrupted time series analysis was conducted using Clinformatics Data Mart claims data (2008-2019). Two cohorts were analyzed: infants (< 2 years) and children (2-18 years). The primary outcome was quarterly SCA diagnostic rates.
resultsDuring the pre-intervention period (2008-2013), 197 infants and 1477 children were diagnosed with an SCA, compared with 373 infants and 1300 children post-intervention (2014-2019). Introduction of prenatal cfDNA screening was associated with an immediate increase in SCA diagnosis rates among infants (3.55-6.56 cases per 100,000 persons), followed by a post-intervention average increase of 0.233 cases per 100,000 persons per quarter. Both the level (p = 0.03) and trend (p = 0.002) changes were statistically significant for infants compared with children.
conclusionsPrenatal cfDNA screening was associated with an immediate and sustained increase in SCA diagnosis rates among infants, whereas no meaningful change was observed among children, suggesting that cfDNA screening may contribute to more frequent detection of SCAs earlier in life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.